Focused On-demand Library for Cartilage intermediate layer protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O75339

UPID:

CILP1_HUMAN

Alternative names:

Cartilage intermediate-layer protein

Alternative UPACC:

O75339; B2R8F7; Q6UW99; Q8IYI5

Background:

Cartilage intermediate layer protein 1, alternatively known as Cartilage intermediate-layer protein, plays a crucial role in cartilage scaffolding. It is instrumental in modulating key growth factors, notably by antagonizing the functions of TGF-beta1 (TGFB1) and IGF1. This protein's ability to suppress IGF1-induced proliferation and sulfated proteoglycan synthesis, alongside inhibiting IGF1R autophosphorylation, underscores its regulatory significance in cartilage dynamics.

Therapeutic significance:

Given its involvement in Intervertebral disc disease, a condition marked by the degeneration of lumbar spine intervertebral disks leading to pain, the study of Cartilage intermediate layer protein 1 holds promise for novel therapeutic strategies. Its regulatory role in cartilage matrix composition and potential to influence disease progression makes it a target of interest in musculoskeletal disorder treatment.